Long-term outcome of intravitreal pegaptanib sodium as maintenance therapy in Japanese patients with neovascular age-related macular degeneration

Japanese Journal of Ophthalmology

Volumn 59, Issue 3, 2015, Pages 173-178

  Inoue, Maiko ^a   Kadonosono, Kazuaki ^a   Arakawa, Akira ^a   Yamane, Shin ^a   Ishibashi, Tatsuro ^b  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Age related macular degeneration; Maintenance therapy; Pegaptanib sodium; Ranibizumab

Indexed keywords

ANGIOGENESIS INHIBITOR; APTAMER; PEGAPTANIB; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG EFFECTS; EPIDEMIOLOGY; ETHNOLOGY; FEMALE; FOLLOW UP; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; JAPAN; MAINTENANCE CHEMOTHERAPY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; VERY ELDERLY; VISUAL ACUITY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; APTAMERS, NUCLEOTIDE; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; JAPAN; MAINTENANCE CHEMOTHERAPY; MALE; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84939945997     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-015-0374-4     Document Type: Article

References (19)

1. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol. 1988;32:375–413.
2. Bressler NM, Bressler SB, Congdon NG, Ferris FL 3rd, Friedman DS, Klein R, et al. Potential public health impact of age-related eye disease study results: Areds report No. 11. Arch Ophthalmol. 2003;121:1621–4.
3. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA Ophthalmol. 2004;291:1900–1.
4. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640–2.
5. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.
6. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:1868–75.
7. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(57–65):e55.
8. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Group S-US. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–9.
9. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, Group VISiONCT. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–16.
10. Gonzales CR, Group VISiONCT. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina. 2005;25:815–27.
11. Friberg TR, Tolentino M. Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study. Br J Ophthalmol. 2010;94:1611–7.
12. Ishibashi T, Group L-JS. Maintenance therapy with pegaptanib sodium for neovascular age-related macular degeneration: an exploratory study in Japanese patients (LEVEL-J study). Jpn J Ophthalmol. 2013;57:417–23.
13. Shiragami C, Ono A, Kobayashi M, Manabe S, Yamashita A, Shiraga F. Effect of switching therapy to pegaptanib in eyes with the persistent cases of exudative age-related macular degeneration. Medicine. 2014;93:e116.
14. Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98.
15. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.
16. Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology. 2009;116:362.
17. Ueta T. Safety in aflibercept versus ranibizumab. Ophthalmology. 2014;121:e5.
18. Rosenfeld PJ, Shapiro H, Tuomi L, Webster M, Elledge J, Blodi B, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology. 2011;118:523–30.
19. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53–67.